Clinical Trial Results:
            A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-2)
    
|     Summary | |
|     EudraCT number | 2006-001403-11 | 
|     Trial protocol | DE PT ES HU AT CZ GR IT | 
|     Global completion date | 
                                    28 Jan 2009
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    01 Jul 2016
                             | 
|     First version publication date | 
                                    01 Jul 2016
                             | 
|     Other versions | |
|     Summary report(s) | 102672-Clinical-Study-Result-Summary | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
